Noor Aliza Lodz, Nurdiyana Farhana Mat Tamizi, Mohd Hatta Abd Mutalip, Shubash Shander Ganapathy, Chong Zhuo Lin, Rohani Ismail, Noor Ani Ahmad

Anti-S Antibodies Against SARS-CoV-2 Infection Among Four Types of Vaccines in Malaysia

  • Public Health, Environmental and Occupational Health
Save to CiteDrive Show PDF

Monitoring SARS-CoV-2 antibody levels can provide insights into a person’s immunity to COVID-19 and inform decisions about vaccination and public health measures. Anti-S may be useful as an indicator of an effective immune response. Thus, we conducted this study that aims to determine the immune response of anti-S antibodies against SARS-CoV-2 for all the vaccine types over time among adult recipients in Malaysia and to determine the associated factors. This study was a cohort that recruited 2513 respondents aged 18 years and above from June 2021 to December 2021. Each participant was followed-up for 1-year period from the initial vaccine dose (baseline). We found that the anti-S antibody generally increased for all vaccine types and peaked at 2 weeks after the second dose vaccination, with Pfizer recipients having the highest median of 100 (100.00-100.00). During the third-month follow-up, the seropositivity of anti-S antibody and the median level decreased for all vaccines. We found that type of vaccines, comorbid status, infection, and booster status were significantly associated with the anti-S antibody level after 1 year.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

  • Web-based, modern reference management
  • Collaborate and share with fellow researchers
  • Integration with Overleaf
  • Comprehensive BibTeX/BibLaTeX support
  • Save articles and websites directly from your browser
  • Search for new articles from a database of tens of millions of references
Try out CiteDrive

More from our Archive